Creo Medical has made strong progress since its IPO, achieving regulatory approvals for its products and first in-human application of its device to remove a colorectal lesion. We maintain the view that the company's ground-breaking technology, which facilitates a broad range of therapeutic interventions to be performed through an endoscope, will stimulate significant interest in the +$3bn global endoscopy market with minimal direct competition. We maintain our Buy recommendation.
02 Aug 2018
Cenkos: Creo Medical Group Plc - Delivering on expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc - Delivering on expectations
Creo Medical Group Plc (CREO:LON) | 34.2 0 0.0% | Mkt Cap: 123.8m
- Published:
02 Aug 2018 -
Author:
Chris Donnellan -
Pages:
22
Creo Medical has made strong progress since its IPO, achieving regulatory approvals for its products and first in-human application of its device to remove a colorectal lesion. We maintain the view that the company's ground-breaking technology, which facilitates a broad range of therapeutic interventions to be performed through an endoscope, will stimulate significant interest in the +$3bn global endoscopy market with minimal direct competition. We maintain our Buy recommendation.